Recurrent spontaneous abortion (RSA) refers to the loss of the fetus 3 or more times before 28 weeks of gestation according to the usual definition in China, but it is also believed that the second consecutive procedure should be valued and evaluated.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Bio-Rad Laboratories reported after the close of the market recently that its second quarter revenues increased 14 percent year over year, driven by growth in both its Life Science and Clinical Diagnostics businesses. For the three months e

Expedeon reported today a 106 percent jump in its second quarter revenues as the biological products and services company wrapped up the integration of several recent acquisitions. For the three-month period ended June 30, Expedeon which jus

NEW YORK (GenomeWeb) Shanghai, China-based cancer precision medicine company OrigiMed said today it will collaborate with Illumina to develop oncology assays. The firms will develop the new assays on Illuminas next-generation sequencing inst

Illumina reported after the close of the market on Monday that its second quarter 2018 revenues rose by 25 percent year over year. The San Diego-based genomics technology company reported total Q2 revenues of $830 million, compared to $662 m

Expedeon reported today a 106 percent jump in its second quarter revenues as the biological products and services company wrapped up the integration of several recent acquisitions. For the three-month period ended June 30, Expedeon which jus

CHICAGO AACC welcomed thousands of medical professionals and healthcare leaders at the 70thAACC Annual Scientific Meeting Clinical Lab Expo from July 29 August 2. The meeting showcased advancements in clinical testing technology and researc

The global critical care diagnostics (CCD) market is estimated to have been valued at USD 837.6 million in 2015 and is expected to reach USD 1.3 billion by 2024, driven by increasing awareness among physicians, patients requirements for cost

Finnishconsumer genetic testing firm Negen has turned to BC Platforms for analysis ofraw genomic data for clinical reporting purposes, the companies announced recently. Underterms of the new partnership, BC Platforms will run data collected

Bio-Rad Laboratories reported after the close of the market recently thatits second quarter revenues increased 14 percent year over year, driven bygrowth in both its Life Science and Clinical Diagnostics businesses. For the three months end

PerkinElmer, Women Infants Hospital of Rhode Island to Test NIPT System PerkinElmer said recently that it is collaborating with Women Infants Hospital (WIH) of Rhode Island toevaluate the performance of its Vanadis noninvasive prenatal test